Macrolides for the therapy of nosocomial infections

Current Opinion in Infectious Diseases

Volumn 25, Issue 2, 2012, Pages 205-210

  Mouktaroudi, Maria ^a   Giamarellos Bourboulis, Evangelos J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

cytokines; macrolides; pneumonia; Pseudomonas aeruginosa

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; FLAGELLIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; APOPTOSIS; ARTIFICIAL VENTILATION; CHLAMYDOPHILA PNEUMONIAE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE EXACERBATION; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; HAEMOPHILUS; HOSPITAL INFECTION; HUMAN; IMMUNOMODULATION; INFLUENZA VIRUS A H3N2; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; LYMPHOCYTE; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; MYCOPLASMA PNEUMONIAE; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NONHUMAN; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; RESPIRATORY TRACT INFECTION; REVIEW; SEPTIC SHOCK; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; SURVIVAL RATE; UREAPLASMA UREALYTICUM; VENTILATOR ASSOCIATED PNEUMONIA;

ANIMALS; CLINICAL TRIALS AS TOPIC; CROSS INFECTION; CYTOKINES; HUMANS; MACROLIDES; MACROPHAGES, ALVEOLAR; MICE; MONOCYTES; PSEUDOMONAS AERUGINOSA; RABBITS; RATS; RESPIRATORY TRACT INFECTIONS;

EID: 84858003959     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834ff1b4     Document Type: Review

References (25)

1. Rosenthal VD, Bijie H, Maki DG, et al. International nosocomial infection control consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am J Infect Control 2011. [Epub ahead of print]
2. Kim YJ, Yoon JH, Kim SI, et al. High mortality associated with Acinetobacter species infection in liver transplant patients. Transplant Proc 2011; 43:2397-2399.
3. Lye DC, Earnest A, Ling ML, et al. The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: cohort study. Clin Microbiol Infect 2011. [Epub ahead of print]
4. Giamarellos-Bourboulis EJ. Macrocycle molecules for the management of systemic infections: the clarithromycin paradigm. Curr Top Med Chem 2010; 10:1470-1475.
5. Wang H, Chen M, Xu Y, et al. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the community-acquired respiratory tract infection pathogen surveillance (CARTIPS) study, 2009-2010. Int J Antimicrob Chemother 2011; 38:376-383.
6. Pérez-Trallero E, Martín-Herrero JE, Mazón A, et al. Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). Antimicrob Agents Chemother 2010; 54:2953-2959. A study describing the change of susceptibility patterns of respiratory pathogens from a vast collection in Spain
7. Hicks LA, Chien YW, Taylor TH Jr, et al. Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clin Infect Dis 2011; 53:631-639.
8. Togami K, Chono S, Morimoto K. Distribution characteristics of clarithromycin and azithormycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages. Biopharm Drug Dispos 2011; 32:389-397. An experimental study in rats and in epithelial cell lines showing the different pharmacokinetic profiles of clarithromycin and of azithromycin in the lung.
9. Kinjo Y, Illarionov P, Vela JL, et al. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol 2011; 12:966-975. The first study recognizing glycolipids of Streptococcus pneumoniae as efficient PAMPs.
10. Giamarellos-Bourboulis EJ, van de Veerdonk, Mouktaroudi M, et al. Inhibition of caspase-1 activation in Gram-negative sepsis and experimental endotoxemia. Crit Care 2011; 15:R27. A large survey showing downregulation of cytokine production by circulating monocytes in sepsis.
11. Yamaya M, Shinya K, Hatachi Y, et al. Clarithromycin inhibits type A seasonal influenza virus infection in human airway epithelial cells. J Pharmacol Exp Ther 2010; 333:81-90.
12. Araki N, Yanagihara K, Morinaga Y, et al. Azithromycin inhibits nontypeable Haemophilucs influenzae-induced MUC5AC expression and secretion via inhibition of activator protein-1 in human airway epithelial cells. Eur J Pharmacol 2010; 644:209-214.
13. Nakamura S, Yanagihara K, Araki N, et al. Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. Antimicrob Agents Chamother 2010; 54:757-762.
14. Feola DJ, Gravy BA, Cory TJ, et al. Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. Antimicrob Agents Chemother 2010; 54:2437-2447. An experimental study showing how treatment with azithromycin changes phenotype characteristics of alveolar macrophages.
15. Atmatzidis S, Koutelidakis I, Chatzimavoudis G, et al. Clarithromycin modulates immune responses in experimental peritonitis. Int J Antimicrob Agents 2011; 37:347-351. Using a unique study model by sequential monitoring of the immune function after start of therapy, the efficacy of clarithromycin in the phase of immunoparalysis of sepsis was suggested.
16. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365:689-698. The first large randomized study showing a positive effect of azithromycin in preventing exacerbation of chronic obstructive pulmonary disease.
17. Kamatkar NG, Shrout JD. Surface hardness impairment of quorum sensing and swarming for Pseudomonas aeruginosa. PloS One 2011; 6:e20888. A study showing the role of quorum sensing for swarming motility of Pseudomonas aeruginosa.
18. Lintz MJ, Oinuma KI, Wysoczynski CL, et al. Crystal structure of QscR, a Pseudomonas aeruginosa quorum sensing signal receptor. Proc Natl Acd Sci USA 2011; 108:15763-15768.
19. Halldorsson S, Gudjonsson T, Gottfredsson M, et al. Azithormycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection. Am J Resp Crit Care Med 2010; 42:62-68. The presence of quorum sensing rhls disrupts transepithelial resistance and tight junctions between epithelial cells of the airways; this is restored by the addition of azithromycin.
20. Köhler T, Perron GG, Buckling A, van Delden C. Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa. PLoS Pathog 2010; 6:e1000883. A randomized trial in mechanically ventilated patients colonized by Pseudomonas aeruginosa showing decreased gene expression of quorum sensing components in the tracheal aspirates after intravenous treatment with azithromycin.
21. Cai Y, Chai D, Wnag R, et al. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J Antimicrob Chemother 2011; 66:968-978.
22. Li H, Zhou Y, Fan F, et al. Effect of azithromycin on patients with diffuse panbronchiolitis obliterans: retrospective study of 51 cases. Intern Med 2011; 50:1663-1669.
23. Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Resp J 2009; 33:153-159. A retrospective cohort analysis of 237 patients with severe sepsis due to CAP indicating an outcome benefit by addition of a macrolide to the treatment regimen.
24. Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36:612-620.
25. Giamarellos-Bourboulis EJ, Pechère JC, Routsi C, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008; 46:1157-1164. The only available randomized clinical trial showing benefit from administration of clarithromycin in patients with ventilator-associated pneumonia. (Pubitemid 351589897)